Quantifying disease progression in amyotrophic lateral sclerosis

NG Simon, MR Turner, S Vucic… - Annals of …, 2014 - Wiley Online Library
Amyotrophic lateral sclerosis (ALS) exhibits characteristic variability of onset and rate of
disease progression, with inherent clinical heterogeneity making disease quantitation …

Primary lateral sclerosis: a distinct entity or part of the ALS spectrum?

E Finegan, RH Chipika, SLH Shing… - … Lateral Sclerosis and …, 2019 - Taylor & Francis
Primary lateral sclerosis (PLS) has been traditionally viewed as a distinct upper motor
neuron condition (UMN) but is increasingly regarded as a sub-phenotype within the …

An miRNA fingerprint using neural-enriched extracellular vesicles from blood plasma: towards a biomarker for amyotrophic lateral sclerosis/motor neuron disease

SA Banack, RA Dunlop, PA Cox - Open biology, 2020 - royalsocietypublishing.org
Biomarkers for amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) are currently
not clinically available for disease diagnosis or analysis of disease progression. If identified …

[HTML][HTML] miRNA extracted from extracellular vesicles is a robust biomarker of amyotrophic lateral sclerosis

SA Banack, RA Dunlop, EW Stommel, P Mehta… - Journal of the …, 2022 - Elsevier
Background and objectives We examined miRNA biomarkers for ALS extracted from
extracellular vesicles in blood samples using a large and diverse patient and control …

Tracking a fast-moving disease: longitudinal markers, monitoring, and clinical trial endpoints in ALS

RH Chipika, E Finegan, S Li Hi Shing… - Frontiers in …, 2019 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) encompasses a heterogeneous group of phenotypes
with different progression rates, varying degree of extra-motor involvement and divergent …

Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration

P Bede, O Hardiman - Amyotrophic Lateral Sclerosis and …, 2018 - Taylor & Francis
Background: Cross-sectional imaging studies offer valuable pathological insights into the
neurodegenerative changes of amyotrophic lateral sclerosis. However, clinical trials urgently …

Imaging cerebral activity in amyotrophic lateral sclerosis

M Proudfoot, P Bede, MR Turner - Frontiers in neurology, 2019 - frontiersin.org
Advances in neuroimaging, complementing histopathological insights, have established a
multi-system involvement of cerebral networks beyond the traditional neuromuscular …

Spinal cord imaging in amyotrophic lateral sclerosis: historical concepts—novel techniques

MM El Mendili, G Querin, P Bede, PF Pradat - Frontiers in neurology, 2019 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) is the most common adult onset motor neuron disease
with no effective disease modifying therapies at present. Spinal cord degeneration is a …

Long non-coding and coding RNAs characterization in peripheral blood mononuclear cells and spinal cord from amyotrophic lateral sclerosis patients

S Gagliardi, S Zucca, C Pandini, L Diamanti… - Scientific reports, 2018 - nature.com
Alteration in RNA metabolism, concerning both coding and long non-coding RNAs
(lncRNAs), may play an important role in Amyotrophic Lateral Sclerosis (ALS) pathogenesis …

Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics

C Schuster, O Hardiman, P Bede - BMC neurology, 2017 - Springer
Background Amyotrophic lateral sclerosis (ALS) a highly heterogeneous neurodegenerative
condition. Accurate diagnostic, monitoring and prognostic biomarkers are urgently needed …